Although further studies are needed to confirm the long-term effects, recent studies have shown the infliximab biosimilar to be a safe, effective, and cost reducing treatment for inflammatory bowel diseases.
The infliximab (IFX) biosimilar CT-P13 (Remsima) is equally effective and safe as its reference drug at treating inflammatory bowel diseases (IBDs) while also being more cost effective, according to a recent study.
IBDs are a few of many chronic conditions which have had treatment affected by biological drugs, but the cost of biologics has risen in the past 2 decades. Biosimilars have proven to be a safe and effective alternative, both in adults and in pediatric patients.
Biosimilars, “highly similar” version of their reference drugs, have seen more use as the price of biologics rises or as patents expire. Clinical trials have primarily been used to prove their safety and effectiveness in adults. Recently, however, more data on the safety and effectiveness of biosimilars in pediatric patients has been recorded.
The European Society of Pediatric Gastroenterology, Hepatology and Nutrition found CT-P13 can be used as a reliable alternative to IFX in pediatric patients. Other pediatric studies have shown IFX biosimilars to be similarly safe and effective to the reference drug. As these studies were of a small sample size and varying follow-up lengths, more data is needed to confirm their accuracy.
In the pediatric population, there is a concern about the interchangeability between the CT-P13 biosimilar and the IFX reference drug. The safety of non-medical switching between the IFX drug to a biosimilar was tested in a systematic review, analyzing 44 studies consisting of 3 randomized controlled trials, 40 observational trials, and 1 case series. There were no negative impacts recorded on safety, efficacy, or immunogenicity, but the small number of randomized controlled trials leaves the data unconclusive.
Long term, biosimilars will reduce the cost of biologic therapy, making treatment more affordable and accessible. They are 15% to 45% cheaper than their reference drugs, and in Europe the price reductions on certain biosimilars have reached 80%.
Currently, biosimilars are deemed a safe and effective substitute for treatment of IBDs. Further studies will be necessary to fill in the gaps in the data that is currently available.
The article originally appeared on Contemporary Pediatrics.
Reference
1. Dipasquale V, Cucinotta U, Romano C. Biosimilars in pediatric IBD: updated considerations for disease management. Biologics. 2022;16:57-66. doi: 10.2147/BTT.S367032
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
Read More
FDA grants FTD to nipocalimab for treating FNAIT
March 26th 2024The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.
Read More
Study links low neighborhood food access to adverse birth outcomes
March 26th 2024A recent study highlighted the link between residence in low-income areas with limited food access during pregnancy and increased risks of lower birth weight and small for gestational age infants, urging further investigation into potential interventions for improved birth outcomes.
Read More